WithdrawnNCT07307768
Ketamine Biomarker Validation
Medication studyAges 18–59United StatesDepression
Understand this study
Who could participate?
Listed age limits: 18 years to 59 years.
- Listed locations
- New YorkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: December 20, 2025
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- Soterix Medical
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 59 Years
- Official registry ID
- NCT07307768
- Official title
Show the full official title
EEG Biomarker Development for Ketamine Administration
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Soterix Medical.
Does this study involve medication?
Yes. The study involves medication, including Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg) and Ketamine (0.75 mg/kg).
Who can participate?
Listed age limits: 18 years to 59 years.
Is this study still recruiting?
The registry lists this study as withdrawn.
